Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 2/20 | 0.42 |
| ▸ | CCKBR | P32239 | 5/20 | 0.41 |
| ▸ | GLP1R | P43220 | 4/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.40 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30517378 | 0.93 | PCSK9 (0.45) | KISS1RCCKBRPCSK9CXCR4IL23R | |
| SCHEMBL30517354 | 0.92 | CXCR4 (0.45) | KISS1RCCKBRPCSK9CXCR4IL23R | |
| SCHEMBL30517386 | 0.88 | CXCR4 (0.48) | KISS1RCXCR4IL23ROPRD1 | |
| SCHEMBL30517372 | 0.88 | KISS1R (0.42) | KISS1RCCKBRPCSK9CXCR4IL23R | |
| SCHEMBL30517370 | 0.87 | PCSK9 (0.47) | KISS1RCCKBRPCSK9CXCR4IL23R | |
| SCHEMBL30517398 | 0.87 | KISS1R (0.42) | KISS1RCCKBRPCSK9CXCR4IL23R | |
| SCHEMBL30517366 | 0.86 | KISS1R (0.44) | KISS1RCCKBRCXCR4IL23RCCKAR | |
| SCHEMBL30517383 | 0.86 | IL23R (0.47) | KISS1RCCKBRPCSK9CXCR4IL23R | |
| SCHEMBL31130668 | 0.85 | CXCR4 (0.48) | KISS1RPCSK9CXCR4IL23RPRMT1 | |
| SCHEMBL30517374 | 0.85 | PCSK9 (0.46) | CCKBRPCSK9CXCR4IL23RKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220001-A1 | METHOD FOR SYNTHESIS OF THIOETHER-CONTAINING PEPTIDES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220001-A1 | METHOD FOR SYNTHESIS OF THIOETHER-CONTAINING PEPTIDES | TST, PTMS, CTH | KISS1R 894/4885CCKBR 94/4885GLP1R 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.